A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden

被引：3

作者：

Rebeck, Olivia N. ^{[1
,2
]}

Wallace, Miranda J. ^{[1
,2
]}

Prusa, Jerome ^{[1
,2
]}

Ning, Jie ^{[1
,2
]}

Evbuomwan, Esse M. ^{[1
,2
,3
]}

Rengarajan, Sunaina ^{[1
,4
]}

Habimana-Griffin, Lemoyne ^{[1
,5
]}

Kwak, Suryang ^{[1
,2
]}

Zahrah, David ^{[1
]}

Tung, Jason ^{[1
]}

Liao, James ^{[1
,2
]}

Mahmud, Bejan ^{[1
,2
]}

Fishbein, Skye R. S. ^{[1
,2
]}

Tovar, Erick S. Ramirez ^{[1
,2
]}

Mehta, Rehan ^{[1
,2
]}

Wang, Bin ^{[1
,2
]}

Gorelik, Mark G. ^{[1
,2
]}

Helmink, Beth A. ^{[6
]}

Dantas, Gautam ^{[1
,2
,3
,7
,8
]}

机构：

[1] Washington Univ, Sch Med, Edison Family Ctr Genome Sci & Syst Biol, St Louis, MO 63110 USA

[2] Washington Univ, Sch Med, Dept Pathol & Immunol, Div Lab & Genom Med, St Louis, MO 63110 USA

[3] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA

[4] Washington Univ, Sch Med, John T Milliken Dept Internal Med, Div Dermatol, St Louis, MO 63110 USA

[5] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA

[7] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA

[8] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA

来源：

CELL CHEMICAL BIOLOGY | 2025年 / 32卷 / 01期

基金：

美国国家卫生研究院;

关键词：

MONOCLONAL-ANTIBODY THERAPY; SACCHAROMYCES-BOULARDII; GUT MICROBIOME; RESISTANCE; CANCER; IMMUNOTHERAPY; MECHANISMS; PREVENTION; EFFICACY;

D O I：

10.1016/j.chembiol.2024.10.013

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Engineered probiotics are an emerging platform for in situ delivery of therapeutics to the gut. Herein, we developed an orally administered, yeast-based therapeutic delivery system to deliver next-generation immune checkpoint inhibitor (ICI) proteins directly to gastrointestinal tumors. We engineered Saccharomyces cerevisiae var. boulardii (Sb), a probiotic yeast with high genetic tractability and innate anticancer activity, to secrete "miniature"antibody variants that target programmed death ligand 1 (Sb_haPD-1). When tested in an ICI-refractory colorectal cancer (CRC) mouse model, Sb_haPD-1 significantly reduced intestinal tumor burden and resulted in significant shifts to the immune cell profile and microbiome composition. This oral therapeutic platform is modular and highly customizable, opening new avenues of targeted drug delivery that can be applied to treat a myriad of gastrointestinal malignancies.

引用

页数：21

共 50 条

[41] Immune checkpoint inhibitors could reduce the circulating tumor cell counts in patients with unresectable urothelial carcioma of the bladder
Huang, Haichao
Xing, Jinchun
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 31 - 31
[42] The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC Reply
Ricciuti, Biagio
Awad, Mark M.
JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
[43] Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis
Li, Yan
Ma, Yiqi
Wu, Zijun
Zeng, Fanxin
Song, Bin
Zhang, Yanrong
Li, Jinxing
Lui, Su
Wu, Min
FRONTIERS IN IMMUNOLOGY, 2021, 12
[44] Association of KMT2C/D Mutations with Tumor Mutation Burden and Response to Immune Checkpoint Inhibitors in NSCLC
Liu, R.
Niu, Y.
Ma, T.
Yuan, H.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S546 - S546
[45] Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer
Liddell, Savannah S.
Chakrabarti, Sakti
Wintheiser, Grant A.
Zemla, Tyler J.
Shi, Qian
Tella, Sri Harsha
Jin, Zhaohui
Wookey, Vanessa B.
Hassan, Hind
Tran, Nguyen H.
Borad, Mitesh J.
Mahipal, Amit
JCO PRECISION ONCOLOGY, 2022, 6
[46] The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
Wu, Yongfeng
Xu, Jinming
Du, Chengli
Wu, Yihua
Xia, Dajing
Lv, Wang
Hu, Jian
FRONTIERS IN ONCOLOGY, 2019, 9
[47] Panel-derived tumor mutational burden (TMB) correlates with immune checkpoint inhibitors (ICIs) response in gastrointestinal cancers
Chen, San-chi
Tan, Kien-Thiam
Chen, Ming-Huang
Hung, Yi-Ping
Hsieh, Yi-Lin
Jan, Yi-Hua
Chao, Yee
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[48] Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma
Fangshi Xu
Yibing Guan
Peng Zhang
Li Xue
Yubo Ma
Mei Gao
Tie Chong
Bin-Cheng Ren
BMC Endocrine Disorders, 22
[49] Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors
Yu, James
Park, Robin
Miao, Ruoyu
Imanirad, Iman
Shahzad, Moazzam
Laborde, Jose M.
Knepper, Todd C.
Walko, Christine M.
Kim, Richard
JOURNAL OF IMMUNOTHERAPY, 2024, 47 (09) : 378 - 383
[50] Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies
Chyuan, I-Tsu
Chu, Ching-Liang
Hsu, Ping-Ning
CANCERS, 2021, 13 (06) : 1 - 14

← 1 2 3 4 5 →